Alzamend Neuro Reports Death of Director Lynne Fahey McGrath

What Happened
Alzamend Neuro, Inc. (ALZN) filed an 8-K (dated July 21, 2026) announcing that director Lynne Fahey McGrath, M.P.H., Ph.D., passed away on July 20, 2026. Dr. McGrath had served on the company’s Board of Directors since the company’s initial public offering in June 2021. Chairman William B. Horne issued a statement expressing the Board’s condolences and noting her contributions to corporate governance and biopharmaceutical strategy.

Key Details

• Filing: Form 8-K, Item 8.01 (Other Events), filed July 21, 2026.
• Date of death: July 20, 2026.
• Board tenure: Director since Alzamend Neuro’s IPO in June 2021.
• Company comment: Chairman William B. Horne praised her governance insight and biopharma expertise.

Why It Matters
Dr. McGrath’s passing creates a vacancy on Alzamend’s Board and removes a long-standing director with biopharmaceutical experience. The filing does not state a replacement or timing for any board appointment. Investors should note this change in corporate governance and watch for any subsequent filings or announcements about a new director or related board actions.